Altagracia Alcantara Gonzalez, MD
Endocrinology, Diabetes & Metabolism · Bayamon, PRNPI 1376505586
Payments from drug & device makers
Across 420 payments — averaging $2385.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly Export S.A. Puerto Rico Branch$889K
- Eli Lilly$42K
- AbbVie$30K
- Johnson & Johnson$16K
- Lilly USA, LLC$14K
- Sanofi-aventis U.S. LLC$6K
- plus $5K from 12 others
Across 30 payments — averaging $20,555 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly Export S.A. Puerto Rico Branch$469K
- Eli Lilly$147K
- AbbVie$815
What the payments were for
- Consulting fees$6,05011%
- Speaking & faculty fees$38,30967%
- Travel & lodging$5,0159%
- Food & beverage$8,13014%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly Export S.A. Puerto Rico Branch | 64 | $888,879 |
| Eli Lilly | 47 | $42,080 |
| AbbVie | 17 | $29,768 |
| Johnson & Johnson | 48 | $16,098 |
| Lilly USA, LLC | 32 | $14,156 |
| Sanofi-aventis U.S. LLC | 36 | $6,077 |
| Merck | 21 | $1,517 |
| Novo Nordisk | 53 | $1,047 |
| AstraZeneca | 45 | $988 |
| Abbott | 17 | $343 |
| Dexcom, Inc. | 16 | $316 |
| Boehringer Ingelheim | 8 | $286 |
| Amgen | 8 | $177 |
| Medtronic | 2 | $59 |
| Bayer | 2 | $48 |
| PBG Puerto Rico LLC | 2 | $45 |
| Verity Pharmaceuticals Inc. | 1 | $25 |
| Pfizer Pharmaceuticals LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,001,927 in reported general payments places this provider in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 753 | $527,876 |
| OzempicSemaglutide | 461 | $462,564 |
| TrulicityDulaglutide | 293 | $300,118 |
| JardianceEmpagliflozin | 327 | $253,727 |
| SynthroidLevothyroxine Sodium | 3,604 | $223,872 |
| MounjaroTirzepatide | 157 | $169,022 |
| JanumetSitagliptin Phos/Metformin Hcl | 173 | $118,855 |
| Xigduo XrDapaglifloz Propaned/Metformin | 168 | $110,505 |
| ProliaDenosumab | 56 | $99,407 |
| RybelsusSemaglutide | 89 | $94,863 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 133 | $94,156 |
| JanuviaSitagliptin Phosphate | 121 | $92,832 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 126 | $84,658 |
| GlyxambiEmpagliflozin/Linagliptin | 107 | $80,268 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 78 | $62,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Trijardy Xr, Tradjenta | $286 | $652,778908 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humalog Mix 75-25, Humulin 70-30 | $14,156 | $567,072960 claims |
| Novo NordiskOzempic, Rybelsus | $1,047 | $557,427550 claims |
| AstraZenecaFarxiga | $988 | $527,876753 claims |
| MerckJanumet, Janumet Xr, Januvia | $1,517 | $305,843427 claims |
| AbbVieSynthroid, Linzess | $29,768 | $242,2353,638 claims |
| AmgenProlia | $177 | $99,40756 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $6,077 | $60,738234 claims |
| Johnson & JohnsonXarelto | $16,098 | $35,46453 claims |
| BayerKerendia | $48 | $14,59722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in Bayamon
- Angel Comulada RiveraBayamon$8.9M
- Paola Mansilla-LetelierBayamon$3.1M
- Jean Pujals KuryBayamon$50K
- Gloria Vega CarattiniBayamon$26K
- Hiram Maldonado RiveraBayamon$7K
- Ramon Ortiz CarrasquilloManati$6M
- Alex Gonzalez BossoloSan Juan$5.5M
- Martha GomezSan Juan$3.8M
- Myriam Allende-VigoHumacao$963K
- Jose Garcia MateoPonce$945K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.